Exciting news for Antineo !

We are proud to announce the award of EUROSTARS funding for the project SyNaPoC, carried out in collaboration with the start-up Polyceutix and DTU - Technical University of Denmark.

This ambitious project aims to develop PLX-001, a next-generation innovative immunotherapy based on nanodisc-forming polymers.

The aim is to stimulate the immune system directly at the tumor site, in order to improve treatment of muscle-invasive bladder cancer and other solid tumors.

Over 24 months, we will validate the preclinical safety and efficacy of this disruptive approach and build the scientific foundation paving the way to first-in-human clinical trials.

For Antineo, this project is also a unique opportunity to develop new PDX models and strengthen our expertise in in-vivo models and preclinical oncology evaluation.

One step closer to more effective, targeted, and accessible therapeutic solutions for patients.